Next Article in Journal
Physical Examination for Endocrine Diseases: Does It Still Play a Role?
Previous Article in Journal
Parameters for Calcium Metabolism in Women with Polycystic Ovary Syndrome Who Undergo Stimulation with Letrozole: A Prospective Cohort Study
Previous Article in Special Issue
Determinants of Quality of Life in Adult Patients with Chronic Non-Bacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region (SCCH): A Dutch Single Center Study
 
 
Review
Peer-Review Record

Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy

J. Clin. Med. 2022, 11(9), 2595; https://doi.org/10.3390/jcm11092595
by Jakob Höppner 1, Kathrin Sinningen 1, Adalbert Raimann 2, Barbara Obermayer-Pietsch 3 and Corinna Grasemann 1,*
Reviewer 1: Anonymous
Reviewer 2:
J. Clin. Med. 2022, 11(9), 2595; https://doi.org/10.3390/jcm11092595
Submission received: 31 March 2022 / Revised: 29 April 2022 / Accepted: 1 May 2022 / Published: 5 May 2022
(This article belongs to the Special Issue Recent Advances in the Management of Rare Metabolic Bone Diseases)

Round 1

Reviewer 1 Report

In the present review Höppner et al analyze the genetics, pathophysiology and management of disorders of the calcium sensing signaling pathway. The article is interesting and well-written

Comments

  1. Are there differences in presentation/diagnosis between sporadic cases of CaSR sensing or signaling reduction and genetic ones?
  2. Page 3 – lines 77-78: “Stimulation of the CaSR by hypercalcemia leads to inhibition of osteoclastic resorption and increased osteoblastic activity”. However, these effects do not result in increased bone mass as indirectly concluded by the lack of BMD changes with calcium only supplementation or calcimimetic administration or in prolonged hypercalcemic states
  3. In section 4.1 please quote changes in other parameters (serum and urinary phosphate, Mg, 25OHD, 1,25(OH)2D)
  4. Do patients with FHH have reduced bone mass or increased fracture risk due to chronically increased PTH?
  5. What is the mechanism of hypermagnesemia in FHH3?

Minor comments

  1. Abstract – page 1 – line 20: “conditions” instead of “a condition”
  2. Page 1 – line 28: “this is based” instead of “this based”
  3. Line 194: “FHH and PHPT” instead of “FHH to PHPT”?

Author Response

We thank the Reviewers for the review of our manuscript and the helpful comments and suggestions. Below we have answered in a point-by-point response. The requested changes are highlighted in the manuscript and are copied into the point-by-point rebuttal for easier referral.

Author Response File: Author Response.docx

Reviewer 2 Report

GENERAL COMMENT

The authors reviewed the literature on FHH, focusing on neonatal severe hyperparathyroidism (NSHPT)

I suggest to add the aims at the end of Introduction section

The paper is a narrative review, nevertheless, I recommend adding a brief Methods section in which you should report the period of inclusion, the databases searched, and the selection criteria.

Lines 223: I recommend to point out that the thyroid gland must be spared (10.1016/j.ijsu.2014.05.042)

The author should add the meaning of all acronyms used in the figures

Figure 4: I suggest to improve the quality of graphs

The authors should complete the sections under the Summary

Author Response

We thank the Reviewers for the review of our manuscript and the helpful comments and suggestions. Below we have answered in a point-by-point response. The requested changes are highlighted in the manuscript and are copied into the point-by-point rebuttal for easier referral.

Author Response File: Author Response.docx

Back to TopTop